The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Adjuvant pembrolizumab for participants with hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation: The phase 3 keynote-937 study.
 
Stephen Chan
Honoraria - AstraZeneca; Eisai; Elevar Therapeutics; Ipsen; MSD (Inst); Roche
Consulting or Advisory Role - AstraZeneca; Eisai; Elevar Therapeutics; Exelixis; MSD Oncology; Roche
Research Funding - Eisai; MSD
Travel, Accommodations, Expenses - Ipsen; Roche
 
Mohamed Bouattour
Research Funding - MSD (Inst)
 
Thomas Yau
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - MSD (Inst)
 
Ann-Lii Cheng
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb/Ono Pharmaceutical; Eisai; IPSEN; MSD Oncology; Roche
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; BeiGene; Genentech/Roche; Ipsen; IQVIA; MSD; Omega Therapeutics, Inc.; Roche
Travel, Accommodations, Expenses - AstraZeneca; Roche
 
Yabing Guo
Research Funding - MSD (Inst)
 
Chuang Peng
Research Funding - MSD (Inst)
 
Do Young Kim
Research Funding - MSD (Inst)
 
Lipika Goyal
Consulting or Advisory Role - Abbvie; Alentis Therapeutics; AstraZeneca; Black Diamond Therapeutics; Blueprint Medicines; Cogent Biosciences; Compass Therapeutics; Eisai/H3 Biomedicine; Exelixis; Genentech; Kinnate Biopharma; Merck; QED Therapeutics; Revolution Medicines; SERVIER; Sirtex Medical; Surface Oncology; Synthekine; Taiho Pharmaceutical; TransThera Biosciences; Tyra Biosciences
Research Funding - Alyssum (Inst); Genentech (Inst)
(OPTIONAL) Uncompensated Relationships - Agios; Boehringer Ingelheim; Boehringer Ingelheim; Debiopharm Group; Merck; Taiho Pharmaceutical
 
Long-Bin Jeng
Research Funding - MSD (Inst)
 
Ming-Chin Yu
Research Funding - MSD (Inst)
 
Seung Woon Paik
No Relationships to Disclose
 
Valeriy Breder
Honoraria - AstraZeneca; Roche
Consulting or Advisory Role - AstraZeneca; Bayer; Roche
 
Robert Martin
Consulting or Advisory Role - AngioDynamics
Research Funding - Merck Sharp & Dohme (Inst)
 
Arndt Vogel
No Relationships to Disclose
 
Masatoshi Kudo
Honoraria - AstraZeneca; Chugai/Roche; Eisai
Consulting or Advisory Role - AstraZeneca; Chugai/Roche; Eisai
Research Funding - Eisai (Inst); GE Healthcare (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst)
 
Jimin Wu
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Usha Malhotra
Employment - Merck
Leadership - Ricovr Healthcare Inc. (I)
Stock and Other Ownership Interests - Merck; Ricovr Healthcare Inc. (I)
 
Abby Siegel
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Josep Llovet
Consulting or Advisory Role - Abbvie; Astrazeneca; Bayer; Eisai; Exelixis; Genentech; Glycotest; Merck; Moderna Therapeutics; Roche; Sanofi
Research Funding - Bayer (Inst); Eisai (Inst)
Travel, Accommodations, Expenses - Bayer
 
Jia Fan
Research Funding - MSD (Inst)